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Abstract
Background: Dual antiplatelet therapy is usually superior to mono therapy in preventing recurrent vascular events 
(VEs). This systematic review assesses the safety and efficacy of triple antiplatelet therapy in comparison with dual 
therapy in reducing recurrent vascular events.
Methods: Completed randomized controlled trials investigating the effect of triple versus dual antiplatelet therapy in 
patients with ischaemic heart disease (IHD), cerebrovascular disease or peripheral vascular disease were identified 
using electronic bibliographic searches. Data were extracted on composite VEs, myocardial infarction (MI), stroke, death 
and bleeding and analysed with Cochrane Review Manager software. Odds ratios (OR) and 95% confidence intervals 
(CI) were calculated using random effects models.
Results: Twenty-five completed randomized trials (17,383 patients with IHD) were included which involving the use of 
intravenous (iv) GP IIb/IIIa inhibitors (abciximab, eptifibatide, tirofiban), aspirin, clopidogrel and/or cilostazol. In 
comparison with aspirin-based therapy, triple therapy using an intravenous GP IIb/IIIa inhibitor significantly reduced 
composite VEs and MI in patients with non-ST elevation acute coronary syndromes (NSTE-ACS) (VE: OR 0.69, 95% CI 
0.55-0.86; MI: OR 0.70, 95% CI 0.56-0.88) and ST elevation myocardial infarction (STEMI) (VE: OR 0.39, 95% CI 0.30-0.51; 
MI: OR 0.26, 95% CI 0.17-0.38). A significant reduction in death was also noted in STEMI patients treated with GP IIb/IIIa 
based triple therapy (OR 0.69, 95% CI 0.49-0.99). Increased minor bleeding was noted in STEMI and elective 
percutaneous coronary intervention (PCI) patients treated with GP IIb/IIIa based triple therapy. Stroke events were too 
infrequent for us to be able to identify meaningful trends and no data were available for patients recruited into trials on 
the basis of stroke or peripheral vascular disease.
Conclusions: Triple antiplatelet therapy based on iv GPIIb/IIIa inhibitors was more effective than aspirin-based dual 
therapy in reducing VEs in patients with acute coronary syndromes (STEMI and NSTEMI). Minor bleeding was increased 
among STEMI and elective PCI patients treated with a GP IIb/IIIa based triple therapy. In patients undergoing elective 
PCI, triple therapy had no beneficial effect and was associated with an 80% increase in transfusions and an eightfold 
increase in thrombocytopenia. Insufficient data exist for patients with prior ischaemic stroke and peripheral vascular 
disease and further research is needed in these groups of patients.
Background
Platelets contribute to the pathogenesis of different vas-
cular syndromes including myocardial infarction (MI),
ischaemic stroke and peripheral artery disease. Antiplate-
let therapy offers partial prevention of these events[1-4].
The current therapeutic strategies for inhibiting platelets
include: inhibition of cyclooxygenase (for example, aspi-
rin [5]); inhibition of phosphodiesterases III and V and
uptake by red cells of adenosine (for example, cilostazol,
dipyridamole); blockade of the platelet ADP P2Y12
receptor (for example, ticlopidine, clopidogrel, prasugrel);
blockade of glycoprotein IIb/IIIa receptors (which pre-
vents fibrinogen binding); and increasing nitric oxide lev-
els (for example, triflusal). While most antiplatelet agents
are usually given orally, glycoprotein IIb/IIIa receptor
antagonists can be given intravenously (for example,
abciximab, eptifibatide, tirofiban) or orally (for example,
lotrafiban, orbofiban, sibrafiban, xemilofiban). However,
oral IIb/IIIa receptor antagonists have been abandoned
due to an increase in death in several trials[6].
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Individual antiplatelet agents reduce recurrent events
by 15%-20%, as seen with aspirin and dipyridamole [7,8]
and from indirect comparisons for clopidogrel, triflusal
and cilostazol[9-11]. These drugs have different mecha-
nisms of action so their combination is likely to be addi-
tive and more effective in reducing vascular events than
monotherapy, a hypothesis confirmed for aspirin and
clopidogrel [12-15] and aspirin and dipyridamole [8,16].
As a result, guidelines now recommend dual combina-
tions for patients with non-ST elevation with acute coro-
nary syndromes (NSTE-ACS), ST elevation with
myocardial infarction (STEMI), percutaneous coronary
infarction (PCI) and ischaemic stroke/transient ischae-
mic attack (TIA) [17-20]. However, the combination of
aspirin and clopidogrel is not recommended for long-
term prophylaxis (> 12 months) against stroke because of
excess bleeding, as seen in MATCH and CHA-
RISMA[21,22]. Further, in the setting of high risk NSTE-
ACS (patients having elevated troponins, ST depression,
or diabetes) addition of eptifibatide or tirofiban to oral
antiplatelet agents is recommended for initial early treat-
ment (class II, a level A)[19,20]. Addition of abciximab to
aspirin and clopidogrel is also recommended in both
NSTE-ACS and STEMI patients undergoing PCI (for
NSTE-ACS class 11 level B)[19,20]. However, in patients
with recent stroke, the PRoFESS trial found that the com-
bination of aspirin plus extended release dipyridamole
versus clopidogrel had a comparable effect on secondary
stroke prevention[23]. However, the benefit of combined
antiplatelet therapy during high risk acute ischaemic
stroke/TIAs is still unknown.
If two agents are superior to one, then three might be
even better providing that bleeding does not become a
limiting factor. Several randomized trials have compared
triple antiplatelet therapy with dual therapy and we have
assessed these in a systematic review involving patients
with ischaemic vascular diseases.
Methods
Ethics
No ethical approval was required for this study.
Search strategy
Completed randomized controlled trials that investigated
the effect of triple antiplatelet versus dual antiplatelet
therapy in the prevention of vascular events in patients
with ischaemic vascular diseases [stroke/TIA, ischaemic
heart disease (IHD), peripheral vascular disease (PVD)]
were sought with searches (October 2009) of electronic
databases including Cochrane Library (issue 4 2009),
EMBASE, MEDLINE and Science Citation Index (ISI
Web of Science). Separate search strategies were devel-
oped for each database using the following keywords: 'tri-
ple antiplatelet therapy', 'aggressive antiplatelet therapy',
'combined antiplatelet therapy', 'antiplatelet therapy',
'aspirin', 'dipyridamole', 'clopidogrel', 'ticlopidine', 'prasu-
grel' 'cilostazol', 'triflusal', 'abciximab', 'tirofiban', 'eptifi-
batide', 'ST elevation myocardial infarction', 'non-ST
elevation acute coronary syndrome', 'stroke', 'transient
ischaemic attack', 'acute limb ischaemia', 'peripheral arte-
rial/vascular disease', 'vascular events', 'randomized con-
trolled trials' and 'controlled clinical trials'. Reference lists
of earlier reviews [24,25] and identified trial publications
were also checked for additional trials. Where duplicate
publications were identified, data from the primary
report were used. Publications could be in any language.
Selection
Completed randomized, placebo or open-label, con-
trolled trials were included where adult patients who
were at high risk of ischaemic VEs were enrolled: NSTE-
ACS; STEMI; PVD; acute ischaemic stroke; TIA; and pre-
vious MI/or coronary artery disease (secondary preven-
tion), including elective PCI; previous stroke and/or TIA;
and peripheral arterial disease. Patients had to have been
treated with triple antiplatelet therapy versus dual anti-
platelet therapy. Trials where only a sub-set of patients
were offered triple therapy were not included.
Validity assessment
Trials were identified based on the inclusion/exclusion
criteria discussed above. Methodological quality of the
trials was assessed in relation to randomization and con-
cealment of allocation. A quality scale was used to assess
the trials: (A) true randomization and allocation con-
cealed; and (B) process of randomisation not given and
concealment of allocation unclear. This approach is rec-
ommended by the Cochrane collaboration[26].
Data abstraction
Two reviewers identified and assessed published trials.
One author resolved disagreements on studies by discus-
sion (PB).
Study characteristics
The following information were extracted by treatment
group: (i) treatment, including type and route of anti-
platelet administration, treatment window, length of
treatment, and follow up period; (ii) number of patients;
and (iii) outcome, this encompassing: composite vascular
events (non fatal stroke, non-fatal myocardial infarction
or death), myocardial infarction, ischaemic stroke, death,
major bleeding, intracranial bleeding, minor bleeding,
blood transfusions and thrombocytopenia. Outcome
events were based on the definitions used in the individ-
ual trial publications. The primary outcome comprised
composite vascular events; other events were regarded as
secondary outcomes.Geeganage et al. BMC Medicine 2010, 8:36
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Quantitative data synthesis
Data were entered into and analysed using the Cochrane
Collaboration Review Manager software (version 4.2).
Data were analysed separately by indication (NSTE-ACS,
STEMI, PCI, ischaemic stroke, TIA, PVD and indicator
drug in addition to the overall assessment of each vascu-
lar outcome. Odds ratios (OR) and 95% confidence inter-
v a l s  ( C I )  w e r e  c a l c u l a t e d ;  r a n d o m - e f f e c t s  m o d e l s  w e r e
used since heterogeneity was expected among the trials
taking account that different antiplatelet agents and
patient populations were being studied. Heterogeneity
was calculated using the Chi-squared and I2 statistics. An
OR < 1 suggests a beneficial effect whilst an OR > 1 sug-
gest a detrimental drug effect. Absolute event rates for
composite VE (primary outcome) and bleeding were cal-
culated. The event rates for patients receiving triple ther-
apy was calculated from the relative risk and control
event rate for each outcome because the unequal ran-
domization in some trials makes exact rates in the treat-
ment group unreliable ('Simpson paradox'). Egger's test
and Beggs funnel-plot were performed to assess any pub-
lication bias in included trials[27].
Results
Trial flow/flow of included studies
Twenty-five completed randomized trials fulfilled the
inclusion criteria (Table 1) and included 17,383 patients
(Figure 1). Seven trials (771 patients) were excluded (Fig-
ure 1), mostly because they did not provide relevant out-
come data or did not have a control group; an eighth trial
is ongoing.
Study characteristics
The included trials studied three patient populations:
NSTE-ACS (four trials), STEMI (8) and elective PCI (13)
(Table 1). No studies in patients with previous stroke or
PVD were identified. Each of the 25 trials was random-
ized and 17 had concealed allocation; allocation conceal-
ment was unclear in eight studies[28-35]. All trials
compared triple antiplatelet therapy with dual therapy
(Table 1). Most trials used an intravenous GP IIb/IIIa
receptor antagonist as the additional antiplatelet agent
(no studies used an oral GP IIb/IIIa receptor antagonist,
presumably because of hazard with these agents [6]); the
remaining trials used clopidogrel or cilostazol as the extra
agents. No triple therapy trials involved dipyridamole, tri-
flusal or prasugrel. Twenty trials gave concomitant hepa-
rin to both treatment groups. Hence, the comparison of
triple versus conventional antiplatelet therapy was not
confounded (Table 1). No evidence of publication bias
using Egger's test (P for bias 0.97) was present and there
was no asymmetry on visual inspection of the Begg's fun-
nel plot (not shown).
Quantitative data synthesis
GP IIb/IIIa inhibitors
A 30% reduction in composite vascular events (non fatal
stroke, non-fatal myocardial infarction or death) and MI
alone were seen when GP IIb/IIIa inhibitors were added
to dual antiplatelet therapy in patients with NSTE-ACS
(Table 2, Figures 2 and 3); a similar magnitude reduction
in death was also present although this was non-signifi-
cant due to the small number of events. Similarly, vascu-
lar events and MI were reduced by 60%-70% in patients
with STEMI with the addition of GP IIb/IIIa inhibitors;
death was also reduced by 30% (Table 2, Figure 4). GPIIb/
IIIa inhibitors were significantly more effective in pre-
venting vascular events and MI in patients with STEMI
than NSTEMI (chi-square = 10.7, 1 df, P  <0.01; chi-
square = 18.8, 1 df, P  <0.001, respectively). Trends to
reduced vascular events; MI and death were present for
GPIIb/IIIa based triple therapy in patients having elective
PCI. Only six ischaemic strokes were recorded as an out-
come and these came from just four studies; when
assessed there was no difference in ischaemic stroke
between triple and dual antiplatelet therapy (OR 1.74,
95% CI 0.35-8.65, P = 0.5, I2 = 0%).
Other agents
Neither clopidogrel nor cilostazol, when added to dual
antiplatelet therapy (based either aspirin + clopidogrel or
aspirin + GP IIb/IIIa inhibitor), had significant effects on
vascular events in patients with STEMI or having elective
PCI (Table 2). However, the number of trials and patients
in the comparisons was relatively small.
Adverse events
A significant increase in minor bleeding (and trend to
increase in major bleeding) was seen with the use of GP
IIb/IIIa based triple therapy in patients with STEMI or
having PCI (Table 3). As a result, transfusion needs were
increased by 80% with GP IIb/IIIa based triple therapy in
elective PCI patients. Thombocytopenia was increased
eightfold with GP IIb/IIIb based triple therapy in elective
PCI patients (Table 3).
Absolute event rates
Absolute event rates for composite vascular event, major
bleeding and minor bleeding are shown in Figure 5. The
number of patients benefiting from triple antiplatelet
therapy (reduced composite vascular event) was much
larger than the number suffering from major bleeding
(Figure 5).
Discussion
The premise of this systematic review was that if two
antiplatelet agents are usually superior to one, then three
might be better still. Multiple trials were identified which
included different groups of patients (NSTE-ACS,Geeganage et al. BMC Medicine 2010, 8:36
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STEMI, elective PCI) and add-on drugs (GPIIb/IIIa
inhibitors, clopidogrel, cilostazol). The results confirmed
that triple antiplatelet therapy involving the addition of
a n  i n t r a v e n o u s  G P I I b / I I I a  r e c e p t o r  a n t a g o n i s t  i s  m o r e
effective than dual therapy in reducing vascular events
and MI in patients with NSTE-ACS or STEMI. Death was
also reduced in those with STEMI. Interestingly, the rela-
tive reduction in events appears to be greater in patients
with STEMI than NSTE-ACS. A non-significant trend
towards a reduction in vascular outcomes was also found
in elective PCI patients when treated with a GPIIb/IIIa
receptor antagonist, a finding also reported in one other
systematic review[24]. In contrast, triple antiplatelet ther-
apy based on oral cilostazol had no effect on vascular out-
comes in STEMI and elective PCI patients. Similar results
were noted for clopidogrel based triple therapy although
this assessment was based on few patients and may
reflect a type II error.
Figure 1 Search process for relevant studies.Geeganage et al. BMC Medicine 2010, 8:36
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Previous meta-analysis involving the addition of iv
GPIIb/IIIa inhibitors in the setting of STEMI has revealed
conflicting results. One meta-analysis involving six
STEMI trials showed no significant reduction in death or
recurrent MI[36]. Another showed abciximab as an
adjunctive therapy to STEMI patients undergoing stent
implantation (but not balloon angioplasty) reduced mor-
tality and recurrent MI[37]. A third meta-analysis involv-
ing patients with STEMI undergoing primary angioplasty
found that, combined reduced dose thrombolytic therapy
and GPIIb/IIIa inhibitors was not superior to Gp IIb-IIIa
inhibitors alone[38]. A fourth meta-analysis involving five
Table 1: Included randomized controlled trials.
Control group
Study N Age Male
(%)
Asp TP GP Triple
group
Heparin Length of
treatment
Length of
follow-up
(months)
Quality*
NSTE-ACS
ADVANCE[41] 202 69 68 √ √ Tirofiban √ 48 h 6 A
ELISA-2[42] 328 64 71 √ √ Tirofiban - 12 h 1 A
ISAR-REACT-2[43] 2,022 66 75 √ √ Abciximab √ 12 h 1 A
PROTECT-TIMI-30[44] 857 60 67 √ √ Eptifibatide √ 24 h 48 h A
STEMI
ADMIRAL[45] 300 61 82 √ √ Abciximab √ 12 h 6 A
ACE[46] 400 64 77 √ √ Abciximab √ 12 h 6 A
CADILLAC [47] 2082 60 73 √ √ Abciximab √ 12 h 6 B
Ernst/1[48] 60 61 74 √ √ Abciximab √ 12 h 1 B
Ernst/2[48] 60 60 82 √ √ Tirofiban √ 12 h 1 B
Ernst/3[48] 59 61 76 √ √ Tirofiban high dose √ 12 h 1 B
ISAR 2[30] 401 61 76 √ √ Abciximab √ 12 h 1 B
Neumann[31] 200 60 77 √ √ Abciximab √ 12 h 1 B
Petronio[49] 31 57 87 √ √ Abciximab √ 12 h 1 B
Kim[50] 60 63 70 √ √ Cilostazol √ 1 month 1 B
Elective PCI
Claeys[51] 200 67 70 √ √ Abciximab √ 12 h 6 B
EPISTENT[52] 1,603 59 75 √ √ Abciximab √ 13 h 1 A
ESPRIT[35] 2,064 62 73 √ √ Eptifibatide √ 24 h 1 B
ISAR-REACT[53] 2,159 66 77 √ √ Abciximab √ 12 h 1 A
ISAR-SMART-2[54] 502 66 73 √ √ Abciximab √ 12 h 12 A
ISAR-SWEET[55] 701 68 75 √ √ Abciximab √ 12 h 12 A
TOPSTAR[56] 96 65 75 √ √ tirofiban √ 42 h 9 A
MR PCI/1[57] 60 61 85 √ - √ Clopidogrel √ 30 days 1 A
MR PCI/2[57] 60 56 85 √ - √ Clopidogrel √ 30 days 1 A
DECLARE-Long[58] 500 61 64 √ √ Cilostazol - 6 months 6 A
DECLARE-DIABETES[59] 400 61 58 √ √ Cilostazol - 6 months 6 A
Min[60] 59 62 66 √ √ Cilostazol √ 1 month 6 A
CREST[61] 705 60 74 √ √ Cilostazol - 6 months 6 A
Han[62] 1212 60 73 √ √ Cilostazol - 6 months 12 A
*Quality scale: A, true randomization and allocation concealed; B, process of randomization not given and concealment of allocation unclear.
Asp, aspirin; GP, glycoprotein IIb/IIIa receptor antagonists (abciximab, tirofiban, eptifibatide); MI, myocardial infarction; NSTEACS, non-ST 
elevation acute coronary syndrome; PCI, percutaneous coronary interventions; TP, thienopyridine (clopidogrel, ticlopidine).Geeganage et al. BMC Medicine 2010, 8:36
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STEMI trials showed that the use of abciximab in pri-
mary stenting may reduce death or MI in patients with-
out preprocedural thienopyridine therapy (but not in
those who received thienopyridines)[39]. The present
meta-analysis revealed that the addition of iv GPIIb/IIIa
inhibitors in the treatment of STEMI patients reduces
death, MI and composite vascular outcome. However, the
analysis did not include the effects of GPIIb/IIIa inhibi-
tors among different revascularization therapies of
STEMI patients.
Unsurprisingly, bleeding events tended to be higher in
patients receiving triple antiplatelet therapy although
only the analyses involving a GPIIb/IIIa receptor antago-
nist were associated with significant increases in minor
bleeding, this being present in patients with STEMI and
elective PCI. Supporting this observation was a need for
more blood transfusions in elective PCI. Additionally,
treatment with a GPIIb/IIIa receptor antagonist was also
associated with an increased risk of thrombocytopenia,
again in patients having PCI. However, the balance
between treatment efficacy and hazard remains favour-
able for triple antiplatelet therapy as shown by changes in
the absolute event rates for composite vascular event and
major bleeding.
Importantly, the duration of randomised treatment was
short (12-48 h) in most trials apart from four cilostazol
trials where patients received treatment for 6 months
(Table 1). Further, trial follow-up was also short varying
between 1-12 months. Hence, the superiority of intrave-
nous GPIIb/IIIa receptor antagonist based triple anti-
Figure 2 The effect of triple antiplatelet therapy on vascular event or death.Geeganage et al. BMC Medicine 2010, 8:36
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Page 7 of 14
platelet therapy should only be considered for short-term
treatment. Also important is that most of the trials gave
concomitant heparin to all patients (amounting to qua-
druple antithrombotic therapy in patients receiving three
antiplatelets), which may have contributed to increased
bleeding rates. Heparin might also explain the increased
rate of thrombocytopenia although the treatment dura-
tion was short while thrombocytopenia rates, but not
heparin administration, differed between the treatment
groups. In the present analysis methodological quality of
Figure 3 The effect of triple antiplatelet therapy on myocardial infarction.Geeganage et al. BMC Medicine 2010, 8:36
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the trials were assessed in relation to method of random-
ization and concealment of allocation. Other important
factors such as blinding and loss to follow-up that could
also influence methodological quality were not assessed
in the present analysis.
Whilst the results are clear for patients with STEMI,
NSTE-ACS and PCI, there were only very limited data on
stroke outcome events and it is not clear whether triple
antiplatelet therapy is beneficial among stroke patients.
The search process identified one trial of triple antiplate-
let therapy performed in 17 patients with chronic ischae-
m i c  s t r o k e  o r  T I A  ( n o t  i n c l u d e d  i n  t h i s  a n a l y s i s  a s  i t
compared triple antiplatelet therapy with aspirin based
monotherapy)[40]. Hence, the role of triple therapy in
patients with ischaemic cerebrovascular disease cannot
be commented on. No trials comparing triple versus dual
antiplatelet therapy in patients with PVD was found.
Conclusions
Triple antiplatelet therapy based on iv GPIIb/IIIa inhibi-
tors was more effective than aspirin-based dual therapy
in reducing vascular events, MI and death in patients
with acute coronary syndromes (STEMI and NSTEMI).
A significant increase in minor bleeding complications
was observed among STEMI and elective PCI patients
treated with a GP IIb/IIIa based triple therapy. In patients
undergoing elective PCI, triple therapy had no beneficial
effect and was associated with an 80% increase in transfu-
Figure 4 The effect of triple antiplatelet therapy on death.G
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Table 2: Summary of efficacy for triple antiplatelet therapy in randomised controlled trials (significant effects are in bold).
Patients Intervention Myocardial infarction Composite vascular event Death
Triple
events/total
Control
events/total
OR*
(95% CI)
Triple
events/total
Control
events/total
OR*
(95% CI)
Triple
events/total
Control
events/total
OR* (95% CI)
NSTE-ACS GP IIb/IIIa 195/1848 232/1558 0.70 (0.56-0.88) 202/1848 244/1558 0.69 (0.55-0.86) 14/1848 19/1558 0.72 (0.36-1.43)
STEMI GP IIb/IIIa 32/1771 117/1683 0.26 (0.17-0.38) 88/1771 203/1683 0.39 (0.30-0.51) 56/1771 78/1683 0.69 (0.49-0.99)
Cilostazol 2/30 1/30 2.07 (0.18-24.15)
Elective PCI GP IIb/IIIa 170/3615 244/3614 0.77 (0.54-1.11) 195/3515 268/3514 0.78 (0.54-1.12) 33/3515 37/3514 0.90 (0.55-1.46)
Cilostazol 17/1439 16/1437 1.07(0.53-2.16) 46/1408 57/1409 0.86(0.40-1.85) 20/1439 29/1437 0.70(0.39-1.25)
Clopidogrel 2/60 2/60 0.95 (0.13-6.74)
*Odds ratios (OR) were calculated from random effect models.
CI, confidence interval; NSTE-ACS, non-ST elevation acute coronary syndromes; STEMI, ST elevation myocardial infarction; PCI, percutaneous coronary intervention.G
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Table 3: Summary of adverse events during triple antiplatelet therapy(significant effects are in bold).
Patients Intervention Major bleeding Minor bleeding Blood transfusions Thrombocytopenia
Triple
events/total
Control
events/total
OR *(95% CI) Triple
events/total
Control
events/total
OR* (95% CI) Triple
events/total
Control
events
/total
OR* (95% CI) Triple
events/total
Control
events/total
OR* (95% CI)
NSTE-ACS GP IIb/IIIa 34/1275 30/1274 1.15 (0.69-1.91) 46/1113 34/1111 1.37 (0.81-2.33) 45/1174 36/1173 1.27 (0.81-2.00) 8/1012 0/1010 17.1 (0.99-296.69)
STEMI GP IIb/IIIa 11/255 2/195 1.86 (0.43-8.17) 23/255 7/195 2.73 (1.15-6.46) 10/281 15/272 0.63 (0.28-1.44) 11/238 4/181 1.51 (0.48-4.71)
Cilostazol 0/30 0/30
Elective PCI GP IIb/IIIa 42/3314 34/3309 1.29 (0.70-2.36) 99/3314 62/3309 1.60 (1.16-2.21) 71/3264 40/3263 1.79 (1.14-2.79) 17/2269 0/2250 8.04 (1.82-35.59)
Cilostazol 0/1054 1/1058 0.33 (0.01-8.24) 6/1054 7/1058 0.85(0.28-2.56) 1/450 2/450 0.62 (0.08-5.09)
Clopidogrel 1/60 0/60 3.10 (0.12-79.29) 1/60 0/60 3.10 (0.12-79.23)
*Odds ratios were calculated from random effect models.
NSTE-ACS, non-ST elevation acute coronary syndromes; STEMI, ST elevation myocardial infarction; PCI, percutaneous coronary intervention.Geeganage et al. BMC Medicine 2010, 8:36
http://www.biomedcentral.com/1741-7015/8/36
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sions and an eightfold increase in thrombocytopenia.
Hence, the use of this enhanced platelet strategy depends
on the patient population. The balance between benefit
and hazard in patients treated for NSTE-ACS and STEMI
lay in favour of giving three antiplatelet agents (typically
aspirin, clopidogrel and an intravenous GPIIb/IIIa recep-
tor antagonist) thereby supporting guidelines promoting
this approach[19,20]. However, there were no or only few
data available for the use of triple antiplatelet therapy for
preventing recurrence in patients with chronic IHD,
acute or chronic stroke or peripheral artery disease. Fur-
ther research is now required to assess the role of triple
antiplatelet therapy in such patients.
Appendix
Search strategy: MEDLINE (OVID)
01 triple antiplatelet therapy/
02. triple antiplatelet$.tw.
03. triple therapy.tw.
04. combined antiplatelet/
05. combined antiplatelet.tw.
06. aggressive antiplatelet therapy/
07. aggressive antiplatelet therapy.tw.
08. antiplatelet therapy/
09. antiplatelet therapy.tw.
10. 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10
11. aspirin/
12. dipyridamole/
13. clopidogrel/
14. ticlopidine/
15. prasugrel/
16. cilostazol/
17. triflusal/
18. glycoprotein IIb/IIIa receptor antagonists/
19. abciximab/
20. tirofiban/
21. eptifibatide/
22. 11 or 12 or 13 or 14 or 15 or 16 or 17 or 18 or 19 or
20 or 21
23. 10 and 22
24. ST elevation myocardial infarction/
25. STEMI.tw.
26. non-ST elevation acute coronary syndrome/
27. NSTEACS.tw.
28. acute coronary syndrome/
29. ACS.tw.
Figure 5 Absolute event rates for vascular event or death and bleeding.Geeganage et al. BMC Medicine 2010, 8:36
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30. stroke/
31. transient ischaemic attack/
32. TIA.tw.
33. acute limb ischaemia/
34. peripheral arterial disease/
35. peripheral vascular disease/
36. PVD.tw.
37. 24 or 25 or 26 or 27 or 28 or 29 or 30 or 31 or 32 or
33 or 34 or 35 or 36
38. 23 and 37
39. randomized controlled trials/
40. randomized-controlled-trial.pt.
41. controlled-clinical-trial.pt.
42. random allocation/
43. double-blind method/
44. single-blind method/
45. 39 or 40 or 41 or 42 or 43 or 44
46. exp clinical trials/
47. clinical-trial.pt.
48. (clin$ adj trial$).ti, ab.
49. ((singl$ or doubl$ or trebl$ or tripl$) adj (blind$)).ti,
ab.
50. random$.ti, ab.
51. 46 or 47 or 48 or 49 or 50
52. research design/
53. comparative study/
54. exp evaluation studies/
55. follow-up studies/
56. prospective studies/
57. (control$ or prospective$ or volunteer$).ti, ab.
58. 53 or 54 or 55 or 56 or 57
59. 45 or 51 or 52 or 58
60. 38 and 59
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